Advice for healthcare professionals:
counsel women of childbearing potential about the possible risk of neural tube defects with dolutegravir, including consideration of effective contraceptive measures
discuss the benefits and the risks of continuing treatment with dolutegravir to women who are trying to become pregnant
if a pregnancy is confirmed in the first trimester while a patient is on dolutegravir, the benefits and risks of continuing dolutegravir versus switching to another antiretroviral regimen should be discussed with the patient, taking into account the gestational age and the critical time period of neural tube defect development
report any suspected adverse drug reactions associated with dolutegravir to the Yellow Card scheme
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks – Gilead Sciences, Inc. today announced new, …
>98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks –
Message :
Required fields
– >98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies –
– Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy
® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (
Search jobs Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021
KENILWORTH, N.J. (BUSINESS WIRE) $MRK#MRK Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today upcoming presentations from its HIV clinical development programs that will be featured during the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021), taking place virtually from March 6 – 10, 2021. Presentations will include new data for islatravir, the company’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), which is being developed for HIV treatment and prevention. Merck will share late-breaking Phase 1 study results evaluating a new prototype subdermal drug-eluting implant for extended administration of islatravir for pre-exposure prophylaxis (PrEP). This data will also be featured in the CROI virtual press conference. Throughout the conference, Merck will also share
Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021 investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.